Related Experiment Video

Updated: Jun 16, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

[The effect of simultaneously blocking target epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2

Shi-sheng Li1, Xin Zhang, Jing Xu

  • 1Department of Otorhinolaryngology, Affiliated Xiangya Hospital, Central South University, Changsha, 410008, China.

Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi = Journal of Clinical Otorhinolaryngology Head and Neck Surgery
|February 4, 2010
PubMed
Abstract

Insights

Simultaneously blocking EGFR and COX-2 pathways with Tarceva and celecoxib significantly inhibits NPC cell growth. This combination therapy also induces G1 cell cycle arrest and reduces key protein expressions.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal Growth Factor Receptor (EGFR) and Cyclooxygenase-2 (COX-2) pathways are implicated in cancer progression.
  • Targeting these pathways individually has shown potential in cancer treatment.
  • NPC (Nasopharyngeal Carcinoma) remains a significant health concern, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To investigate the efficacy of simultaneously blocking EGFR and COX-2 pathways in inhibiting cancer cell growth.
  • To evaluate the combined effects of Tarceva (EGFR inhibitor) and celecoxib (COX-2 inhibitor) on CNE-2 cell lines.

Main Methods:

  • Utilized cell growth assays, flow cytometry for cell cycle analysis, and Western blotting for protein expression.
  • Examined the impact of Tarceva and celecoxib, both individually and in combination, on CNE-2 cell lines.
  • Assessed effects on cell growth, cell cycle progression, apoptosis, and levels of p-EGFR and COX-2.

Main Results:

  • Combined treatment demonstrated a significantly higher inhibition rate of cell growth compared to single-agent treatments (P < 0.05).
  • The combination therapy significantly induced G1 cell cycle arrest (P < 0.05) without increasing apoptosis (P > 0.05).
  • Reduced expression of p-EGFR and COX-2 was observed in the combination group compared to other treatment groups.

Conclusions:

  • Simultaneous blockade of EGFR and COX-2 pathways is an effective strategy for inhibiting CNE-2 cell line growth.
  • Combination therapy with Tarceva and celecoxib enhances G1 cell cycle arrest.
  • This approach leads to a significant reduction in p-EGFR and COX-2 expression levels.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...